IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Product Class Date Terms of Agreement
Takesulin (cefsulodin) J N/A Licensed out to Novartis for co-marketing in Japan and
for marketing and co-marketing in certain other non-US
markets. Licensed out to Abbott for Canada. Marketed in
Germany and Austria by Takeda Pharma.
Firstcin (cefozopran), J N/A Co-launched in Japan in 1995 by originator Takeda and
licensee Lederle (Wyeth).
Pansporin T (cefotiam
hexetil),
J N/A Co-marketed in France with Aventis. Cheil is the licensee
for South Korea.
Pansporin (cefotiam) J N/A Licensed out to Novartis for a number of markets outside
Japan. Han Il is the licensee for South Korea.
Bestcall (cefmenoxime) J N/A Co-marketed in Japan with licensee Roche. Han Il is the
licensee for South Korea. Marketed in Germany by
Takeda Pharma.
Canferon-A (interferon
alfa-2a)
Leuplin/Lupron Depot
(leuprorelin)
L N/A Jointly developed with Roche under license from
Genentech and co-marketed with Roche in Japan. Roche
markets it worldwide (including Japan) as Roferon-A.
L N/A Licensed out to Abbott for Canada, Europe, Mexico and
several other Latin American countries. TAP markets it in
the US, and Takeda Pharma in Germany and Austria. The
drug is also marketed for precocious puberty in Germany,
Italy and France, and for breast cancer in Japan, Italy
and France.
Osten (ipriflavone) M N/A Licensed in from Chinoin (now part of Sanofi-Synthelabo)
for Japan and for co-marketing in Italy.
Anpec Takeda (morphine
hydrochloride)
MS Contin Takeda
(morphine sulfate)
N N/A Co-developed and co-launched in Japan with Sankyo,
Shionogi and Dainippon.
N N/A Licensed in from Mundipharma and co-developed and
co-launched in Japan with Sankyo, Shionogi and
Dainippon.
© 2009 IMS Health In cor po rated or its af fil i ates Page 94